Inspire(US:INSP)2026-01-12 22:04Financial Results - Inspire Medical Systems, Inc. announced preliminary and unaudited results for the quarter and full year ended December 31, 2025, with specific figures to be confirmed upon completion of closing procedures[5]. - The company’s financial results remain subject to change based on internal control over financial reporting[6]. Executive Appointment - The company appointed Matthew J. Osberg as Chief Financial Officer, effective after the filing of the Annual Report on Form 10-K for the fiscal year ended December 31, 2025[7]. - The transition of the Chief Financial Officer role follows Richard J. Buchholz's decision to step down in August 2025, with Buchholz serving as interim CFO until the filing of the 2025 10-K[15]. Compensation and Benefits - Mr. Osberg's annual base salary is set at $650,000, with a target annual cash bonus of 70% of his base salary and additional long-term incentive awards[10]. - The company will pay Mr. Osberg a cash sign-on bonus of $600,000, with half paid upon starting and the remainder six months later[11]. - Mr. Osberg is eligible for performance stock units valued at $1,500,000 and restricted stock units also valued at $1,500,000, both vesting based on performance objectives and time[11]. - The employment agreement with Mr. Osberg includes provisions for severance benefits in case of termination without cause[13]. Investor Relations - The company is participating in various meetings with investors and analysts in January 2026, with presentation materials available on its Investor Relations page[17]. Stock Information - Inspire Medical Systems is listed on the New York Stock Exchange under the trading symbol INSP[3].